Pharmaceuticals

Prophase Labs

Prophase Labs released FY2025 Q3 earnings on November 19 During-Market EST, actual revenue USD 883K (forecast USD 5.69M), actual EPS USD -1.6463 (forecast USD -1.1)

Prophase Labs released FY2025 9 Months earnings on November 19 During-Market EST, actual revenue USD 3.561 M, actual EPS USD -1.6206

Prophase Labs released FY2025 Q2 earnings on August 13 During-Market (EST), actual revenue USD 1.247 M (forecast USD 3.55 M), actual EPS USD -1.1 (forecast USD -1.5)

Prophase Labs released FY2025 Semi-Annual Earnings on August 13 During-Market EST, Actual Revenue: USD 2.678 M, Actual EPS: USD -0.0149

Prophase Labs to Release FY2025 Q2 Earnings During Market Hours on August 13, 2025 (EST), Forecast Revenue USD 3.55 M, EPS USD -0.15

ProPhase Labs Inc. Releases Presentation on Transition and Collaboration

ProPhase Labs Receives $500,000 Loan and Issues Warrants

ProPhase Labs Inc. Receives Extension Notice

Prophase Labs announces successful research and plans to commercialize BE-SMART™ test

ProPhase Labs Establishes Clinical Scientific Advisory Board to Support Molecular Test Market Launch

Prophase Labs released FY2025 Q1 earnings on May 20 After-Market EST, actual revenue USD 1.431 M (forecast USD 2.45 M), actual EPS USD 0.1125 (forecast USD -0.18)

ProPhase Labs Reports Q1 Net Income of $3.966 Million

ProPhase Labs Releases BE-Smart Esophageal Cancer Detection and DNA Complete Whole Genome Sequencing Service

Prophase Labs to release FY2025 Q1 earnings report on May 20 After-Market EST, forecast revenue USD 2.45 M, EPS USD -0.18

Prophase Labs released FY2024 Q4 earnings on April 1 Pre-Market (EST), actual revenue 0 USD (forecast 3.77 M USD), actual EPS 0 USD (forecast -0.24 USD)

Prophase Labs released FY2024 annual earnings on April 1 Pre-Market (EST), actual revenue 6.77 M USD (forecast 13.02 M USD), actual EPS -2.6078 USD (forecast -1.27 USD)

Prophase Labs to Release FY2024 Earnings on March 31, Pre-Market EST; Forecasted Revenue: 13.02 M USD, EPS: -1.27 USD

Prophase Labs released FY2024 9 Months Earnings on November 13 Pre-Market EST, Actual Revenue: USD 5.276 M, Actual EPS: USD -1.0189

Prophase Labs released FY2024 Q3 earnings on November 13 Pre-Market (EST), actual revenue USD 1.416 M (forecast USD 2.82 M), actual EPS USD -3.4524 (forecast USD -3.1)

Prophase Labs to Release FY2024 Q3 Earnings on November 13, Pre-Market EST; Forecasted Revenue: 2.82 M USD, EPS: -0.31 USD

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap